布地奈德福莫特罗联合噻托溴铵治疗稳定期哮喘合并COPD患者的临床疗效分析  

Clinical Effect of Budesonide-Formoterol Combined with Tiotropium Bromide in the Treatment of Patients with Stable Asthma and COPD

作　　者：黄雅菲 高振云 刘佳 房树华 Huang Yafei;Gao Zhenyun;Liu Jia;Fang Shuhua(Department of Pharmacy,Nanjing Lishui People's Hospital,Nanjing 211200,China;Department of Respiratory Medicine,Nanjing Lishui People's Hospital,Nanjing 211200,China)

机构地区：[1]南京市溧水区人民医院药剂科,江苏南京211200 [2]南京市溧水区人民医院呼吸内科,江苏南京211200

出　　处：《巴楚医学》2025年第1期109-113,共5页Bachu Medical Journal

基　　金：江苏省药学会—天晴医院药学基金项目(Q202054)。

摘　　要：目的:评价布地奈德福莫特罗+噻托溴铵联合治疗稳定期哮喘合并慢性阻塞性肺疾病(COPD)患者的临床效果。方法:选取南京市溧水区人民医院2020年4月—2022年1月收治的91例稳定期哮喘合并COPD的患者,根据是否加用噻托溴铵粉吸入剂分为两组,其中使用布地奈德福莫特罗粉吸入剂为对照组(n=50),噻托溴铵粉吸入剂+布地奈德福莫特罗粉吸入剂为观察组(n=41)。比较两组患者治疗12个月后的哮喘控制测试评分、COPD患者自我评估测试(CAT)评分、肺功能FEV1/FEV1预计值(%)、欧洲五维生命质量量表(EQ-5D)及不良反应发生情况。结果:治疗12个月后,观察组患者CAT评分[(12.85±1.82)分vs(14.05±1.52)分]明显低于对照组(P<0.05);观察组患者FEV1/FEV1预计值[(65.64±4.64)%vs(63.23±5.42)%]、EQ-5D评分[(0.90±0.03)分vs(0.87±0.03)分]、EQ-VAS评分[(82.63±7.10)分vs(78.60±8.76)分]及治疗有效率(87.80%vs 70.00%)均明显高于对照组(均P<0.05)。结论:布地奈德福莫特罗+噻托溴铵联合治疗方案能有效提高稳定期哮喘合并COPD患者的临床疗效、改善肺功能,从而提高患者生活质量,值得临床上进一步推广应用。Objective:To evaluate the clinical effect of combined treatment with budesonide-formoterol and tiotropium bromide in patients with stable asthma and chronic obstructive pulmonary disease(COPD).Methods:A total of 91 patients with stable asthma and COPD admitted to Nanjing Lishui District People's Hospital from April 2020 to January 2022 were selected and divided into two groups based on whether tiotropium bromide powder was added to their treatment.The control group(n=50)used budesonideformoterol powder inhaler,while the observation group(n=41)used tiotropium bromide powder inhaler in addition to budesonide-formoterol powder inhaler.The asthma control test scores,COPD assessment test(CAT)scores,lung function FEV1-FEV1 predicted value(%),EuroQol five-dimension five-level(EQ-5D)quality of life scale,and adverse reactions were compared between the two groups after 12 months of treatment.Results:After 12 months of treatment,the CAT score of the observation group[(12.85±1.82)vs(14.05±1.52)]was significantly lower than that of the control group(P<0.05);the FEV1/FEV1 predicted value[(65.64±4.64)%vs(63.23±5.42)%],EQ-5D score[(0.90±0.03)vs(0.87±0.03)],EQ-VAS score[(82.63±7.10)vs(78.60±8.76)],and treatment efficiency(87.80%vs 70.00%)were all significantly higher than those of the control group(all P<0.05).Conclusion:The combined treatment of budesonide-formoterol and tiotropium bromide can effectively improve the clinical efficacy and lung function in patients with stable asthma and COPD,thereby enhancing the quality of life of patients,which is worthy of further clinical promotion and application.

关 键 词：哮喘 慢性阻塞性肺疾病 布地奈德福莫特罗 噻托溴铵 

分 类 号：R256.12[医药卫生—中医内科学]